Pills masthead

News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009

2008200720062004

2018 Archives

Nov 12, 2018
--Lannett Locks in $50 Million of Gross Profit for 16-Week Period--

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Amneal Pharmaceuticals, Inc. (Amneal) with regard to Levothyroxine Sodium Tablets USP. Under the...

More
Nov 7, 2018
- Fiscal 2019 First Quarter Net Sales and Adjusted Net Income Ahead of Expectations

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 first quarter ended September 30, 2018. "For the fiscal 2019 first quarter, net sales and adjusted net income...

More
Nov 6, 2018
--Company Has Commenced Launch of Clarithromycin and Expects to Begin Marketing Entacapone In Early Calendar Year 2019--

Lannett Company, Inc. (NYSE: LCI) today announced that it has expanded its agreement with Sunshine Lake LLC, the U.S. subsidiary of the HEC Pharm Group (HEC) of China, to be the exclusive...

More
Nov 1, 2018
--Launch Commenced; First-Time Generic Launch of Levitra®--

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Rivopharm SA to be the exclusive U.S. distributor of Vardenafil Hydrochloride Tablets, 2.5 mg, 5 mg, 10...

More
Nov 1, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 first quarter on Wednesday, November 7, 2018, after the market closes. Lannett...

More
Oct 22, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Adare Pharmaceuticals, Inc., to be the exclusive U.S. distributor of Dexmethylphenidate Hydrochloride...

More
Oct 8, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it has engaged and/or expanded the role of existing advisors to assist in evaluating a range of alternatives regarding the company's debt and...

More
Oct 1, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it commenced marketing five new products in its recently completed fiscal 2019 first quarter, bringing to 12 the total number of products...

More
Aug 28, 2018

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 fourth quarter and full year ended June 30, 2018. "For both the fiscal 2018 fourth quarter and full year, our...

More
Aug 22, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 fourth quarter and full year on Tuesday, August 28, 2018, after the market closes....

More
Aug 20, 2018
--Company Announces Preliminary Fiscal 2018 Fourth-Quarter and Full-Year Financial Results; To Host Conference Call Today at 8 a.m. ET--

Lannett Company, Inc. (NYSE: LCI) today said that its distribution agreement with Jerome Stevens Pharmaceuticals (JSP), which expires on March 23, 2019, will not be renewed. "The Steinlauf family...

More
Aug 3, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive perpetual licensing agreement with Andor Pharmaceuticals, LLC for Methylphenidate Hydrochloride Extended...

More
Jul 23, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it launched four products in June 2018, bringing to seven the total number of products launched since January 1, 2018. The June product...

More
Jun 29, 2018

Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost reduction plan of its subsidiary, Cody Laboratories (Cody), a developer and manufacturer of pain management active...

More
Jun 1, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Levofloxacin Oral...

More
May 21, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dronabinol Capsules...

More
May 7, 2018
--Adjusted EPS Higher Than Expected; Outlook for Fiscal 2018 Net Sales and Adjusted Profitability Affirmed--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 third quarter ended March 31, 2018. "We continue to make good progress executing on our strategic...

More
May 7, 2018
--Transaction Includes 23 Approved and 1 Pending Drug Product Applications, Primarily Oral Solutions--

Lannett Company, Inc. (NYSE: LCI) today announced that it has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International plc for an upfront payment plus...

More
May 3, 2018

Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Deutsche Bank 43rd Annual Health Care Conference at 9:20 a.m. ET, on...

More
May 2, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2018 third quarter on Monday, May 7, 2018, after the market closes. Lannett management will...

More
Apr 30, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that effective July 1, 2018 current director, Patrick LePore, will become chairman of the board of directors, succeeding Jeffrey Farber, who will...

More
Apr 20, 2018
--Company Re-aligns Management Responsibilities--

Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Maureen M. Cavanaugh to the newly created position, senior vice president and chief commercial operations officer, effective...

More
Mar 23, 2018
--Appoints Grant Brock as Vice President Operations, Alicia Evolga as Vice President of Marketing--

Lannett Company, Inc. (NYSE: LCI) today announced the appointments of Grant Brock as vice president operations and Alicia Evolga as vice president of marketing. Grant joined the company last month...

More
Mar 12, 2018

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into separate agreements with three strategic alliance partners. Under two of the agreements, Lannett will serve as the...

More
 
Price Data
NYSELCI